X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (5483) 5483
life sciences & biomedicine (5260) 5260
humans (4921) 4921
male (3858) 3858
animals (3244) 3244
imatinib mesylate (2949) 2949
benzamides (2633) 2633
female (2620) 2620
benzamides - pharmacology (2418) 2418
middle aged (1666) 1666
adult (1656) 1656
oncology (1622) 1622
benzamides - administration & dosage (1508) 1508
pyrimidines - therapeutic use (1476) 1476
pyrimidines - administration & dosage (1472) 1472
piperazines - therapeutic use (1450) 1450
piperazines - administration & dosage (1442) 1442
pharmacology & pharmacy (1407) 1407
mice (1298) 1298
rats (1277) 1277
benzamides - therapeutic use (1227) 1227
aged (1208) 1208
antineoplastic agents - therapeutic use (1067) 1067
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (1042) 1042
treatment outcome (990) 990
dose-response relationship, drug (981) 981
hematology (955) 955
imatinib (839) 839
antineoplastic agents - administration & dosage (826) 826
piperazines - pharmacology (779) 779
neurosciences & neurology (697) 697
neurosciences (679) 679
pyrimidines - adverse effects (648) 648
pyrimidines - pharmacology (641) 641
piperazines - adverse effects (607) 607
abridged index medicus (597) 597
administration, oral (597) 597
rats, sprague-dawley (569) 569
cancer (552) 552
benzamides - adverse effects (541) 541
protein kinase inhibitors - therapeutic use (539) 539
research (539) 539
disease models, animal (538) 538
benzamides - pharmacokinetics (527) 527
chronic myeloid leukemia (512) 512
care and treatment (509) 509
analysis (494) 494
protein-tyrosine kinases - antagonists & inhibitors (486) 486
time factors (485) 485
cell line, tumor (478) 478
antineoplastic agents - adverse effects (465) 465
adolescent (455) 455
medicine & public health (455) 455
drug therapy (454) 454
antineoplastic agents - pharmacology (444) 444
gastrointestinal stromal tumors - drug therapy (427) 427
antineoplastic combined chemotherapy protocols - therapeutic use (422) 422
protein kinase inhibitors - administration & dosage (411) 411
aged, 80 and over (400) 400
drug administration schedule (394) 394
young adult (385) 385
antineoplastic agents (380) 380
drug resistance, neoplasm (374) 374
apoptosis - drug effects (361) 361
antimitotic agents (350) 350
leukemia (349) 349
rats, wistar (348) 348
leukemia, myelogenous, chronic, bcr-abl positive - genetics (330) 330
enzyme inhibitors - pharmacology (321) 321
health aspects (320) 320
mice, inbred c57bl (318) 318
biochemistry & molecular biology (316) 316
mutation (315) 315
benzamides - chemistry (309) 309
protein kinase inhibitors - pharmacology (307) 307
tumors (307) 307
cell proliferation - drug effects (299) 299
leukemia, myelogenous, chronic, bcr-abl positive - pathology (296) 296
cell biology (293) 293
psychiatry (293) 293
fusion proteins, bcr-abl - genetics (290) 290
apoptosis (288) 288
signal transduction - drug effects (284) 284
research article (273) 273
piperidines - pharmacology (272) 272
pyridines - pharmacology (269) 269
dasatinib (267) 267
disease-free survival (265) 265
proteins (264) 264
follow-up studies (260) 260
clinical trials as topic (259) 259
rodents (258) 258
remission induction (247) 247
hemic and lymphatic diseases (244) 244
kinases (244) 244
tyrosine (242) 242
hematology, oncology and palliative medicine (239) 239
dosage and administration (237) 237
prognosis (236) 236
chemotherapy (225) 225
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6903) 6903
Japanese (172) 172
French (95) 95
German (63) 63
Russian (57) 57
Chinese (35) 35
Spanish (33) 33
Italian (13) 13
Hungarian (7) 7
Polish (6) 6
Czech (4) 4
Danish (4) 4
Ukrainian (4) 4
Portuguese (3) 3
Dutch (2) 2
Turkish (2) 2
Hebrew (1) 1
Norwegian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 32, pp. 4017 - 4025
Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of antibiotics, immunosuppressives, antiepileptics, and other drugs, but its... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Thiazoles - blood | Injections, Intravenous | Area Under Curve | Pyrimidines - blood | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Half-Life | Thiazoles - administration & dosage | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Drug Monitoring - methods | Indoles - administration & dosage | Antibodies, Monoclonal - blood | Antibodies, Monoclonal, Humanized | Neoplasms - blood | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Benzenesulfonates - blood | Antineoplastic Agents - pharmacokinetics | Cetuximab | Piperazines - blood | Everolimus | Molecular Targeted Therapy - methods | Dasatinib | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Indoles - blood | Rituximab | Pyrroles - blood | Sirolimus - blood | Evidence-Based Medicine | Imatinib Mesylate | Neoplasms - drug therapy | Sirolimus - administration & dosage | Antibodies, Monoclonal, Murine-Derived - blood | Pyridines - blood | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - blood | Benzamides | Index Medicus
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 07/2009, Volume 157, Issue 5, pp. 831 - 843
Background and purpose:  Buprenorphine displays attributes of opioids, but also some features distinct from them. We examined spinal and supraspinal signal... 
mechanism of action | supraspinal | buprenorphine | analgesia (antinociception) | Supraspinal | Analgesia (antinociception) | Buprenorphine | Mechanism of action | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Fentanyl - administration & dosage | Piperazines - administration & dosage | Narcotic Antagonists - administration & dosage | Serotonin Antagonists - administration & dosage | Phosphoprotein Phosphatases - metabolism | Aminoquinolines - administration & dosage | Injections, Intraventricular | Oligonucleotides, Antisense - metabolism | Male | Opioid Peptides - administration & dosage | Pain - chemically induced | Adrenergic alpha-Antagonists - administration & dosage | Pain - metabolism | GTP-Binding Proteins - genetics | Okadaic Acid - administration & dosage | Brain - metabolism | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Benzamides - administration & dosage | Pain Threshold - drug effects | Anesthetics, Local - administration & dosage | Pertussis Toxin - administration & dosage | Receptor, Serotonin, 5-HT1A - metabolism | Disease Models, Animal | Receptors, Opioid - metabolism | Injections, Spinal | Pyridines - administration & dosage | Pain - prevention & control | Phosphoprotein Phosphatases - antagonists & inhibitors | Yohimbine - administration & dosage | Brain - drug effects | Buprenorphine - administration & dosage | Animals | Signal Transduction - drug effects | Analgesics, Opioid - administration & dosage | Acetylcholine | Mice | Naloxone - administration & dosage | Pain Measurement | Morphine - administration & dosage | Receptors, Opioid - drug effects | Serotonin 5-HT1 Receptor Antagonists | GTP-Binding Proteins - metabolism | Index Medicus | Research Papers
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 0027-8424, 11/2015, Volume 112, Issue 45, pp. 14084 - 14089
Marijuana exerts profound effects on human social behavior, but the neural substrates underlying such effects are unknown. Here we report that social contact... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Endocannabinoids - metabolism | Immunohistochemistry | Piperazines - administration & dosage | Bornanes - administration & dosage | Clozapine - administration & dosage | Nucleus Accumbens - metabolism | Bornanes - pharmacology | Male | Carbamates - administration & dosage | Oxytocin - metabolism | Receptors, Cannabinoid - metabolism | Arachidonic Acids - metabolism | Benzamides - administration & dosage | Clozapine - pharmacology | Piperidines - pharmacology | Social Behavior | Benzamides - pharmacology | Carbamates - pharmacology | Pyrazoles - pharmacology | Piperidines - administration & dosage | Benzodiazepines - pharmacology | Mice, Inbred C57BL | Clozapine - analogs & derivatives | Polyunsaturated Alkamides - metabolism | Piperazines - pharmacology | Cocaine - administration & dosage | Cocaine - pharmacology | Pyrazoles - administration & dosage | Animals | Analysis of Variance | Benzodiazepines - administration & dosage | Signal Transduction - physiology | Mice | Lipids - analysis | Reward | Infusions, Intraventricular | Autism Spectrum Disorder - physiopathology | Influence | Cellular signal transduction | Research | Oxytocin | Analysis | Endocannabinoids | Brain | Autism | Marijuana | Neurotransmitters | Neurons | Rodents | Index Medicus | reward | Biological Sciences | endocannabinoid | oxytocin | anandamide | social behavior
Journal Article
British journal of haematology, ISSN 0007-1048, 01/2015, Volume 168, Issue 1, pp. 69 - 81
Summary Bosutinib is an oral, dual SRC/ABL1 tyrosine kinase inhibitor for resistant/intolerant chronic myeloid leukaemia (CML). We assessed the efficacy and... 
BCR‐ABL1 | CML | tyrosine kinase inhibitor | bosutinib | chronic myeloid leukaemia | Chronic myeloid leukaemia | Tyrosine kinase inhibitor | Bosutinib | BCR-ABL1 | Life Sciences & Biomedicine | Hematology | Science & Technology | Piperazines - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Quinolines - administration & dosage | Nitriles - administration & dosage | Benzamides - administration & dosage | Benzamides - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Odds Ratio | Benzamides - adverse effects | Aniline Compounds - administration & dosage | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Leukemia, Myeloid, Chronic-Phase - diagnosis | Leukemia, Myeloid, Chronic-Phase - mortality | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Quinolines - therapeutic use | Aniline Compounds - therapeutic use | Mutation | Aniline Compounds - adverse effects | Nitriles - adverse effects | Quinolines - adverse effects | Nitriles - therapeutic use | Index Medicus | Haematological Malignancy
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 02/2014, Volume 120, Issue 3, pp. 373 - 380
Journal Article
Respiratory research, ISSN 1465-993X, 12/2011, Volume 12, Issue 1, pp. 1 - 10
As chronic obstructive pulmonary disease (COPD) is a heterogeneous disease it is unlikely that all patients will benefit equally from a given therapy.... 
Medicine & Public Health | Pneumology/Respiratory System | Life Sciences & Biomedicine | Respiratory System | Science & Technology | Humans | Middle Aged | Aminopyridines - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Cyclopropanes - adverse effects | Lung - enzymology | Patient Selection | Cyclopropanes - therapeutic use | Forced Expiratory Volume | Benzamides - administration & dosage | Clinical Trials, Phase III as Topic | Anti-Inflammatory Agents - adverse effects | Benzamides - therapeutic use | Multicenter Studies as Topic | Aminopyridines - therapeutic use | Cyclopropanes - administration & dosage | Phosphodiesterase 4 Inhibitors - administration & dosage | Phosphodiesterase 4 Inhibitors - adverse effects | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - administration & dosage | Female | Benzamides - adverse effects | Aminopyridines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Administration, Oral | Risk Factors | Proportional Hazards Models | Phosphodiesterase 4 Inhibitors - therapeutic use | Treatment Outcome | Lung - physiopathology | Pulmonary Disease, Chronic Obstructive - enzymology | Randomized Controlled Trials as Topic | Lung - drug effects | Aged | Research Design | Pulmonary Disease, Chronic Obstructive - drug therapy | Complications and side effects | Lung diseases, Obstructive | Patient outcomes | Dosage and administration | Research | Roflumilast | Drug therapy | Care and treatment | Bronchitis | Analysis | Studies | Hospitals | Statistical analysis | Mortality | Standard deviation | Hospitalization | Clinical medicine | Regression analysis | Manuscripts | Acquisitions & mergers | Index Medicus
Journal Article